Summary: Researchers have developed a new electroporation approach called burst sine wave electroporation (B-SWE) that shows promise for treating glioblastoma by producing more extensive, controlled disruption of the blood–brain barrier (BBB) than conventional methods. B-SWE may allow greater delivery of therapeutic agents to brain tissue while reducing collateral damage to healthy cells.
This technique could improve treatment options for aggressive brain tumors by enabling targeted drug access with limited non-thermal tissue injury. The reported findings point to a promising, adjustable modality for enhancing drug penetration into the brain and for use in combination with existing surgical and pharmacologic therapies.
Key Facts:
- Burst sine wave electroporation (B-SWE) produces more extensive BBB disruption compared with conventional pulsed square-wave electroporation.
- B-SWE may permit increased penetration of chemotherapeutics, biologics, or immunotherapies into brain tissue.
- The method can minimize ablation of healthy tissue when dosed appropriately, and dose adjustments reduce neuromuscular contractions while preserving BBB effects.
Source: Virginia Tech
Background
Treating brain tumors such as glioblastoma is especially difficult because the blood–brain barrier protects the brain from toxins but also blocks many therapeutic agents. Conventional electroporation-based therapies, like high-frequency irreversible electroporation (H-FIRE), use pulsed square-wave electrical fields to ablate tumor tissue while opening the BBB at the treatment site. Building on prior work supported by National Institutes of Health grants, investigators from Georgia Tech and Virginia Tech explored an alternative waveform design to enhance BBB disruption while reducing damage to healthy tissue.
The study introduces burst sine wave electroporation (B-SWE), which applies short bursts of sinusoidal electrical pulses rather than the standard square pulses. In an in vivo rodent model, researchers performed a direct comparison between equivalent energy B-SWE and H-FIRE waveforms to evaluate BBB disruption volume, tissue ablation, neuromuscular effects, and repair kinetics.
Key outcomes showed that B-SWE induced larger volumes of BBB disruption while producing less non-thermal tissue ablation at equivalent delivered energy. This suggests B-SWE could be optimized to prioritize transient BBB opening over cell destruction when clinically appropriate—for example, following surgical resection of a tumor mass, when the goal is to allow systemic or local therapeutics to penetrate the surrounding brain and eliminate residual cancer cells with limited additional injury.
An initial challenge observed with sinusoidal bursts was increased neuromuscular contractions compared with square-wave H-FIRE. These contractions carry the potential for mechanical stress on the tissue. Importantly, the team demonstrated that lowering the B-SWE amplitude produced comparable BBB disruption while substantially reducing neuromuscular activity, indicating a tunable therapeutic window that balances efficacy and safety.
Repair dynamics also differed: BBB opening induced by B-SWE closed more rapidly than disruption of comparable magnitude created by H-FIRE, supporting B-SWE’s potential as a transient, controllable method for drug delivery. Finite element modeling included in the study further illustrated how B-SWE can expand zones of BBB permeability while decreasing adjacent ablation when parameters are adjusted.
The research team plans to extend these findings into models of actual brain tumors to test how B-SWE performs against established H-FIRE protocols in a disease context. Such follow-up studies will be important to determine optimal dosing strategies, therapeutic combinations, and safety limits before clinical translation.
This project was led by Sabrina Campelo as first author during her Ph.D. work at the Virginia Tech–Wake Forest University School of Biomedical Engineering and Sciences; she is now a postdoctoral fellow at the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. John Rossmeisl, a coauthor and professor at the Virginia–Maryland College of Veterinary Medicine, is among the senior investigators contributing to the work.
About this brain cancer research news
Author: Andrew Mann
Source: Virginia Tech
Contact: Andrew Mann – Virginia Tech
Image: Image credit noted as Neuroscience News
Original Research: Open access. “Burst sine wave electroporation (B-SWE) for expansive blood–brain barrier disruption and controlled non-thermal tissue ablation for neurological disease” by John Rossmeisl et al., published in APL Bioengineering. The study compares B-SWE with pulsed square-wave electroporation technologies and reports on BBB disruption volume, tissue ablation, neuromuscular effects, repair kinetics, and modeling results.
Abstract
Burst sine wave electroporation (B-SWE) for expansive blood–brain barrier disruption and controlled non-thermal tissue ablation for neurological disease
The blood–brain barrier limits the effectiveness of many treatments for malignant brain tumors, prompting the need for new approaches that safely increase drug access. This study introduces burst sine wave electroporation (B-SWE) as a modality designed to produce controlled, expansive BBB disruption while minimizing non-thermal tissue ablation. Using an in vivo rodent model, the authors compare B-SWE with conventional pulsed square-wave electroporation methods such as H-FIRE. Equivalent waveform energy allowed direct comparison: B-SWE produced larger BBB disruption volumes and less tissue ablation. Although B-SWE resulted in greater neuromuscular contractions at matched energy, a reduced-amplitude B-SWE group achieved similar BBB disruption with substantially fewer contractions. Repair kinetics showed faster BBB closure after B-SWE, supporting its transient and controllable nature. Finite element modeling corroborated the potential to maximize BBB opening while limiting ablation. Collectively, these results identify B-SWE as a promising technique for tailored BBB disruption with minimal collateral tissue damage, with applications for glioblastoma therapy and other neurological conditions.